Value Of Magnetic Resonance Spectroscopy And Perfusion-Weighted Imaging In Distinguishing Glioma Recurrence From Ptre: A Meta-Analysis

Yuheng Shan,Xian Chen,Yanchen Lin,Yuliang Wang,Shijiang Zhong,Yanhua Gong
2016-01-01
Abstract:Background and purpose: Nowadays, radiation therapy has become a gold standard treatment for gliomas, especially for high grade gliomas. Unfortunately, posttreatment radiation effect (PTRE) often mimics tumor recurrence, which causes a diagnostic challenge in clinical management. Since traditional magnetic resonance techniques were useless in distinguishing between glioma recurrence and PTRE, advanced magnetic resonance functional imaging methods, for instance magnetic resonance spectroscopy (MRS) and perfusion-weighted imaging (PWI), have been used to distinguish glioma recurrence from PTRE. However, the accuracy of MRS and PWI in distinguishing between glioma recurrence and PTRE is unclear. The purpose of this meta-analysis is to assess the diagnostic value of MRS and PWI in distinguishing glioma recurrence from PTRE. Methods: A comprehensive literature search was accomplished in three databases (PubMed, Web of Science and Embase). Eligible studies were performed in English, aimed to evaluate the performance of MRS, PWI in distinguishing glioma recurrence from PTRE. To assess the quality of included articles, we applied Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) in this meta-analysis. For each study, diagnostic values were extracted or calculated. Sensitivity (SEN), specificity (SPE), likelihood ratio (LR; positive LR/negative LR) and diagnostic odds ratio (DOR) were pooled by using the Stata 13.1 software. Results: 22 eligible articles and 687 patients were included in this meta-analysis. The pooled SEN, SPE, PLR, NLR and DOR for MRS and PWI were 0.92 (0.86-0.96), 0.87 (0.87-0.93), 6.87 (3.86-12.21), 0.09 (0.04-0.17), 48.48 (27.79-221.63) and 0.84 (0.80-0.88), 0.84 (0.79-0.88), 5.51 (3.98-6.89), 0.19 (0.14-0.24), 28.09 (17.63-44.75), respectively. Conclusions: In conclusion, our meta-analysis verified an overall moderate diagnostic performance of MRS and PWI for distinguishing between glioma recurrence and PTRE. Furthermore, both dynamic susceptibility contrast (DSC) perfusion imaging and dynamic contrast enhanced (DCE) perfusion imaging are promising methods in differentiating glioma recurrence from PTRE. In the future, well-designed clinical studies are needed to validate their applicability in differentiating these two lesions.
What problem does this paper attempt to address?